Aprea Therapeutics, Inc. (APRE) |
| 0.8386 -0.022 (-2.5%) 08-28 16:00 |
| Open: | 0.88 |
| High: | 0.9099 |
| Low: | 0.8202 |
| Volume: | 343,096 |
| Market Cap: | 10(M) |
| PE Ratio: | -0.78 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 1.16 |
| Resistance 1: | 0.94 |
| Pivot price: | 0.74 |
| Support 1: | 0.59 |
| Support 2: | 0.49 |
| 52w High: | 1.69 |
| 52w Low: | 0.548 |
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Financials
| EPS | -13200000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -255.00 |
| Return on Assets (ttm) | 25.5 |
| Return on Equity (ttm) | -27.7 |
Company news
Fri, 28 Aug 2026
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs - The Manila Times
Tue, 25 Aug 2026
Aprea Therapeutics records second consecutive surge, jumping another 22% (APRE:NASDAQ) - Seeking Alpha
Tue, 25 Aug 2026
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
Sat, 15 Aug 2026
Aprea Therapeutics (APRE) Edges Higher by 1.34% as Shares Hover Above Key Support - Strangle Setup - vinanet.vn
Thu, 13 Aug 2026
Aprea Therapeutics (APRE) investor Lytton discloses 3.2% ownership in 13G/A - Stock Titan
Wed, 12 Aug 2026
Aprea Therapeutics (NASDAQ: APRE) extends cash runway with $41M balance and trial updates - Stock Titan
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
